New Products In Brief
This article was originally published in The Tan Sheet
Executive Summary
Symbollon takes supplement route: IoGen launches as a dietary supplement for women's breast health after Symbollon Pharmaceuticals' application with FDA seeking medical food approval stalled, said a spokeswoman for the Medfield, Mass., biotech firm. Symbollon completed eight clinical trials evaluating the effects of its molecular iodine compound on mastalgia and fibrosis in more than 2,000 patients. Starting in February, IoGen will be available in health food stores, online and through gynecologists, at a suggested retail price of $29.99 for 30 tablets
You may also be interested in...
Symbollon expands Iogen distribution
New England Vitamin Brokers will expand the presence of Symbollon Pharmaceuticals Inc.'s Iogen women's breast health supplement in New England. Medfield, Mass.-based Symbollon said June 16 it is exploring additional retail distribution channels for Iogen, which launched in February touting clinically proven effects in women with fibrocystic breast disease (1"The Tan Sheet" Feb. 22, 2010). NEVB Director Michael Goolkasian called Iogen "a truly unique product supported by extensive clinical data.
Symbollon expands Iogen distribution
New England Vitamin Brokers will expand the presence of Symbollon Pharmaceuticals Inc.'s Iogen women's breast health supplement in New England. Medfield, Mass.-based Symbollon said June 16 it is exploring additional retail distribution channels for Iogen, which launched in February touting clinically proven effects in women with fibrocystic breast disease (1"The Tan Sheet" Feb. 22, 2010). NEVB Director Michael Goolkasian called Iogen "a truly unique product supported by extensive clinical data.
Symbollon expands Iogen distribution
New England Vitamin Brokers will expand the presence of Symbollon Pharmaceuticals Inc.'s Iogen women's breast health supplement in New England. Medfield, Mass.-based Symbollon said June 16 it is exploring additional retail distribution channels for Iogen, which launched in February touting clinically proven effects in women with fibrocystic breast disease (1"The Tan Sheet" Feb. 22, 2010). NEVB Director Michael Goolkasian called Iogen "a truly unique product supported by extensive clinical data.